Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
作者信息
Glaspy J
机构信息
UCLA School of Medicine, 200 Medical Plaza, Suite 120, Los Angeles, CA, 90024 USA.
出版信息
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):1-2. doi: 10.1054/bjoc.2001.1745.
Abstract
摘要
相似文献
1
Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):1-2. doi: 10.1054/bjoc.2001.1745.
2
Darbepoetin alfa: potential role in managing anemia in cancer patients.
Expert Rev Anticancer Ther. 2002 Aug;2(4):377-84. doi: 10.1586/14737140.2.4.377.
3
Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):11-6. doi: 10.1054/bjoc.2001.1747.
4
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):24-30. doi: 10.1054/bjoc.2001.1749.
5
Darbepoetin alfa for the treatment of cancer-related anemia: an update.
Expert Rev Anticancer Ther. 2004 Oct;4(5):735-44. doi: 10.1586/14737140.4.5.735.
6
CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
Curr Hematol Rep. 2005 Nov;4(6):436-40.
7
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):17-23. doi: 10.1054/bjoc.2001.1748.
8
Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):31-7. doi: 10.1054/bjoc.2001.1750.
9
Phase III clinical trials with darbepoetin: implications for clinicians.
Best Pract Res Clin Haematol. 2005;18(3):407-16. doi: 10.1016/j.beha.2005.02.001.
10
Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull. 2004 Mar;42(3):21-3.
本文引用的文献
1
Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):31-7. doi: 10.1054/bjoc.2001.1750.
2
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):24-30. doi: 10.1054/bjoc.2001.1749.
3
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):17-23. doi: 10.1054/bjoc.2001.1748.
4
Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):11-6. doi: 10.1054/bjoc.2001.1747.
5
Development and characterization of novel erythropoiesis stimulating protein (NESP).
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):3-10. doi: 10.1054/bjoc.2001.1746.
6
Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.
J Am Soc Nephrol. 1999 Nov;10(11):2392-5. doi: 10.1681/ASN.V10112392.
Zotero 插件